We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+50.74%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.11B
AUM Growth
+$318M
Cap. Flow
+$101M
Cap. Flow %
9.09%
Top 10 Hldgs %
61.72%
Holding
56
New
18
Increased
10
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$46.5M
2
ARVN icon
Arvinas
ARVN
+$39.2M
3
ASMB icon
Assembly Biosciences
ASMB
+$35.2M
4
IPHA
Innate Pharma
IPHA
+$27.9M
5
MRUS
Merus
MRUS
+$25M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$69.3M
2
ARGX icon
argenx
ARGX
+$44.5M
3
SLDB icon
Solid Biosciences
SLDB
+$34.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$8.42M

Sector Composition

Rank Sector Weight
1 Healthcare 87.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QNCX icon
51
Quince Therapeutics
QNCX
$18.4M
– –
-250
Closed -$1.25M
RGLS
52
DELISTED
Regulus Therapeutics
RGLS
– –
-104,909
Closed -$755K
SLDB icon
53
Solid Biosciences
SLDB
$832M
– –
-222,846
Closed -$34.6M
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.78B
– –
-189,745
Closed -$14.3M
UBX
55
DELISTED
Unity Biotechnology
UBX
– –
-5,140
Closed -$314K
ONCE
56
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-714,789
Closed -$69.3M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q4 2019 Portfolio in Review

As of Q4 2019, EcoR1 Capital held 56 positions worth $1.11B, up 40% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

EcoR1 Capital deployed $101M of net new capital in Q4 2019, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was AnaptysBio: 1,966,100 shares worth $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 79% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $44.5M trimmed.

  • EcoR1 Capital's largest Q4 2019 buy was AnaptysBio: 1,966,100 shares worth $31.9M.
  • EcoR1 Capital added most to Assembly Biosciences in Q4 2019, an estimated $35.2M increase.
  • EcoR1 Capital's biggest Q4 2019 reduction was argenx, cutting an estimated $44.5M.
  • EcoR1 Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $69.3M.
  • EcoR1 Capital's ten largest holdings make up 62% of its $1.11B portfolio in Q4 2019.
  • EcoR1 Capital opened 18 new positions and closed 12 in Q4 2019.
  • EcoR1 Capital's portfolio value rose 40% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.